Overview of Apellis Pharmaceuticals' Upcoming Event
Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) is connecting with the medical community by hosting a fireside chat as part of a significant event centered around ophthalmology. This event will take place on a Wednesday morning during the UBS Virtual Ophthalmology Day.
Details of the Fireside Chat
The live discussion is set to begin at 8:30 a.m. ET, providing an opportunity for participants to explore the advancements Apellis is making in ophthalmology. The company is eager to share insights about their ongoing projects and their efforts to develop new medical therapies that address serious vision-related challenges.
Accessing the Live Event
If you're interested in watching the fireside chat, you can tune in via the live stream available on the "Events and Presentations" page located within the "Investors and Media" section of Apellis Pharmaceuticals' official website. For those who may miss the live session, a recording will be available for about 90 days, allowing them to catch up on the important insights shared.
Understanding Apellis Pharmaceuticals
Founded to address some of the toughest diseases facing patients, Apellis Pharmaceuticals has made impressive progress in the biopharmaceutical field. They focus on complement-based therapies and have initiated groundbreaking work in treating various medical conditions.
The Impact of Their Innovative Therapies
Apellis distinguishes itself by introducing the first new class of complement medicine in over a decade, showcasing their strong commitment to research and development. Currently, Apellis has two approved medications aimed specifically at C3, marking a notable achievement in the treatment landscape. Importantly, they provide the first and only therapy for geographic atrophy, a leading cause of blindness worldwide, meeting a crucial need for both patients and healthcare providers.
The Promise of Future Developments
Dedicated to improving vision health, Apellis Pharmaceuticals believes that their journey has only just begun. The company is exploring the vast potential of C3-targeted therapies for various severe retinal disorders, rare conditions, and neurological diseases. This commitment not only reflects their scientific courage but also highlights the compassionate approach they take in their research.
Stay Connected with Apellis
If you want to keep up with Apellis Pharmaceuticals, they encourage you to connect through their social media platforms. Whether it's Twitter or LinkedIn, you can follow their updates, research advancements, and announcements that emphasize their steadfast mission to enhance patient outcomes through innovative therapies.
Frequently Asked Questions
What is the UBS Virtual Ophthalmology Day?
The UBS Virtual Ophthalmology Day is an event where various pharmaceutical companies come together to share insights and updates regarding innovations in ophthalmology.
How can I watch the fireside chat hosted by Apellis Pharmaceuticals?
You can access the live event on the "Events and Presentations" page of Apellis Pharmaceuticals' website during the scheduled time or watch the replay afterward.
What are Apellis Pharmaceuticals' main areas of focus?
Apellis primarily concentrates on creating therapies for serious retinal disorders, rare diseases, and neurological conditions, with a strong focus on complement biology.
What is the significance of their C3-targeted therapies?
C3-targeted therapies represent a significant advancement in medicine, addressing critical needs in treating diseases that currently have limited treatment options.
How can I contact Apellis Pharmaceuticals for investor inquiries?
You can direct investor inquiries to Meredith Kaya via the email address listed on their investor relations page, or you can reach her by phone at 617.599.8178.
